Literature DB >> 22327757

Assessment of malignancy rate in thyroid nodules according to the Bethesda system of fine-needle aspiration. Report from a tertiary center in the Southwestern region of Saudi Arabia.

Mubarak M Al-Shraim1, Omaia M Kaood, Mahmoud R Hussein, Ali M Al-Ahmary, Gharamah Y Al Shehri, Raid A Jastania, Ahmed A Mahfouz, Saeed A Abu-Eshy.   

Abstract

OBJECTIVE: To determine the rates of malignancy of thyroid nodules in each standard cytologic diagnostic category of the Bethesda system.
METHODS: In a retrospective cohort study from October 1998 to April 2007 at the Department of Pathology, Aseer Central Hospital, Southwestern region of Saudi Arabia, all cases of thyroid nodules that underwent preoperative cytologic examination by fine-needle aspiration (FNA) and concurrent postoperative histopathologic examination were included. All FNA diagnoses were reclassified using the thyroid FNA Bethesda reporting system, including non-diagnostic (insufficient), benign, atypical follicular lesion of undetermined significance (AFLUS), neoplasm, suspicious of malignancy, and malignant groups. The rate of malignancy based on final histopathologic evaluation was analyzed for each of these cytologic groups.
RESULTS: A total of 323 thyroid fine needle aspiration cytology (FNAC) diagnoses were reclassified into non-diagnostic 6.2%, benign 57.3%, AFLUS 13.6%, follicular and Hurthle cell neoplasms 16.1%, suspicious of malignancy 1.5%, and malignant 5.3% groups. The corresponding rate of malignancy on histopathologic examination was as follows: 35% in the non-diagnostic group, 10.3% in the benign group, 15.9% in AFLUS group, 32.7% in follicular and Hurthle cell neoplasms, 60% in the suspicious of malignancy group, and 94% in the malignant group.
CONCLUSION: Applying a standard terminology reporting system for thyroid FNA may enhance the communication between pathologists and clinicians, assists them to find out the rate of malignancy in each cytologic group, and facilitating a more consistent approach for patients' management.

Entities:  

Mesh:

Year:  2012        PMID: 22327757

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  7 in total

1.  Thyroid cytopathology reporting by the bethesda system: a two-year prospective study in an academic institution.

Authors:  Payal Mehra; Anand Kumar Verma
Journal:  Patholog Res Int       Date:  2015-01-22

2.  The Mcgill thyroid nodule score - does it help with indeterminate thyroid nodules?

Authors:  Rickul Varshney; Veronique-Isabelle Forest; Marco A Mascarella; Faisal Zawawi; Louise Rochon; Michael P Hier; Alex Mlynarek; Michael Tamilia; Richard J Payne
Journal:  J Otolaryngol Head Neck Surg       Date:  2015-02-03

3.  Predictors of a follicular nodule (Thy3) outcome of thyroid fine needle aspiration cytology among Saudi patients.

Authors:  Imad R Musa; Mukhtar El Khatim Ahmad; Fayez Salim Al Raddady; Wesal Rabih Al Rabih; Elsayed M Elsayed; Gussay Badawi Mohamed; Gasim I Gasim
Journal:  BMC Res Notes       Date:  2017-11-23

4.  Thyroid Nodules Cytopathology Applying the Bethesda System with Histopathological Correlation.

Authors:  Hawazen A Zarif; Samirah E Ghandurah; Mohamed A Al-Garni; Sarah K Binmahfooz; Basim S Alsaywid; Mohamed B Satti
Journal:  Saudi J Med Med Sci       Date:  2018-08-14

5.  A study of malignancy rates in different diagnostic categories of the Bethesda system for reporting thyroid cytopathology: An institutional experience.

Authors:  P Arul; C Akshatha; Suresh Masilamani
Journal:  Biomed J       Date:  2016-03-09       Impact factor: 4.910

6.  The Prevalence of Thyroid Papillary Microcarcinoma in Patients With Benign Thyroid Fine Needle Aspiration.

Authors:  Abdullah H Alshathry; Nawaf Z Almeshari; Abdulaziz S Alarifi; Abdullah M Aleidy; Saleh Aldhahri
Journal:  Cureus       Date:  2020-12-01

7.  The prevalence and associated predictors for Bethesda III-VI for reporting thyroid cytopathology in Royal Commission Hospital, Kingdom of Saudi Arabia.

Authors:  Hussain Alyousif; Ishag Adam; Naser A Alamin; Mona A Sid Ahmed; Ayat Al Saeed; Abdulmuhsen Hussein Hassoni; Imad R Musa
Journal:  Ther Adv Endocrinol Metab       Date:  2022-09-12       Impact factor: 4.435

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.